Whitehawk Therapeutics Inc Financials
Whitehawk Therapeutics Inc (WHWK) reported $7.1M in revenue for fiscal year 2025, down 72.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Whitehawk’s FY2025 economics were dominated by equity-funded R&D, with commercial revenue too small to carry the cash burn.
Compared with FY2024, net loss narrowed to$20.6M while operating cash outflow widened to$97.4M . At the same time, financing inflow of$94.4M arrived as shares outstanding nearly doubled, showing liquidity was preserved mainly through new equity rather than internally generated cash.
With revenue of
The balance sheet is lightly levered—total liabilities were only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Whitehawk Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Whitehawk Therapeutics Inc scores 6.55, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($271.4M) relative to total liabilities ($14.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Whitehawk Therapeutics Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Whitehawk Therapeutics Inc reported a net loss of $20.6M while operations used $97.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Whitehawk Therapeutics Inc generated $7.1M in revenue in fiscal year 2025. This represents a decrease of 72.5% from the prior year.
Whitehawk Therapeutics Inc's EBITDA was -$114.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 70.0% from the prior year.
Whitehawk Therapeutics Inc reported -$20.6M in net income in fiscal year 2025. This represents an increase of 67.7% from the prior year.
Whitehawk Therapeutics Inc earned -$0.33 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Whitehawk Therapeutics Inc recorded an outflow of $98.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 60.1% from the prior year.
Whitehawk Therapeutics Inc held $37.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Whitehawk Therapeutics Inc's gross margin was 89.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.
Whitehawk Therapeutics Inc's ROE was -15.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 106.3 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Whitehawk Therapeutics Inc invested $91.0M in research and development in fiscal year 2025. This represents an increase of 78.3% from the prior year.
Whitehawk Therapeutics Inc invested $552K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.6% from the prior year.
Not reported for fiscal year 2025.
WHWK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $7.1M-72.5% | $26.0M+6.7% | $24.4M+60.1% | $15.2M+8.7% | $14.0M0.0% | $14.0M | $0-100.0% | $20.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $760K-74.9% | $3.0M+7.7% | $2.8M+110.4% | $1.3M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $6.4M-72.2% | $23.0M+6.6% | $21.5M+55.2% | $13.9M-0.9% | $14.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $91.0M+78.3% | $51.0M+4.3% | $48.9M+49.8% | $32.7M+66.0% | $19.7M+31.1% | $15.0M+17.0% | $12.8M-28.2% | $17.9M+47.0% | $12.1M+6.9% | $11.4M | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $29.8M-18.8% | $36.7M-17.5% | $44.5M+10.9% | $40.2M+117.0% | $18.5M+772.7% | $2.1M-78.3% | $9.8M-27.7% | $13.5M+45.9% | $9.2M+75.5% | $5.3M+22789.7% | $23K-4.0% | $24K+5.0% | $23K+1.9% | $22K-5.1% | $24K |
| Operating Income | N/A | -$114.4M-69.6% | -$67.5M+6.2% | -$71.9M-14.8% | -$62.7M+43.6% | -$111.2M-4263.2% | -$2.5M+89.6% | -$24.4M-118.6% | -$11.2M+47.7% | -$21.4M | N/A | -$23K+4.0% | -$24K-5.0% | -$23K-1.9% | -$22K+5.1% | -$24K |
| Interest Expense | N/A | $0-100.0% | $154K-33.3% | $231K+0.4% | $230K-65.4% | $665K-18.4% | $815K | N/A | N/A | N/A | $10K+17.9% | $8K+23.5% | $7K+16.2% | $6K+18.2% | $5K+38.2% | $4K |
| Income Tax | N/A | $0 | $0 | $0 | $0-100.0% | $2K0.0% | $2K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$20.6M+67.7% | -$63.7M+3.2% | -$65.8M-8.7% | -$60.5M+45.0% | -$110.1M-3065.3% | -$3.5M+85.1% | -$23.3M-123.8% | -$10.4M+51.4% | -$21.4M | N/A | -$31K | N/A | -$29K-4.9% | -$27K-0.7% | -$27K |
| EPS (Diluted) | — | -$0.33 | -$2.36+3.3% | -$2.44+9.3% | -$2.69 | -$12.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
WHWK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $150.8M+114.5% | $70.3M-46.9% | $132.4M-28.1% | $184.2M+16.7% | $157.9M+738.8% | $18.8M-52.9% | $39.9M-37.7% | $64.1M+204.9% | $21.0M+777.3% | $2.4M+12835.8% | $19K+252.1% | $5K-40.1% | $9K+8.3% | $8K | N/A |
| Current Assets | $149.0M+143.1% | $61.3M-50.8% | $124.6M-30.8% | $180.0M+19.0% | $151.3M+709.6% | $18.7M-52.8% | $39.6M-38.2% | $64.0M+206.2% | $20.9M+838.7% | $2.2M | N/A | N/A | N/A | $8K+22.4% | $7K |
| Cash & Equivalents | $37.6M+31.0% | $28.7M-54.4% | $62.9M+61.2% | $39.0M-73.8% | $149.0M+3244.3% | $4.5M-88.4% | $38.5M-38.5% | $62.6M+209.0% | $20.3M+1158.9% | $1.6M | N/A | $5K-16.2% | $6K+36.4% | $5K+11.7% | $4K |
| Inventory | $0-100.0% | $5.3M-17.4% | $6.4M+245.4% | $1.9M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0-100.0% | $5.9M+7.6% | $5.5M+194.7% | $1.9M | $0-100.0% | $14.1M | N/A | N/A | N/A | $4K | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $14.5M-18.6% | $17.8M-34.5% | $27.2M+5.3% | $25.9M+20.3% | $21.5M-31.2% | $31.3M-36.2% | $49.0M+798.5% | $5.5M+51.9% | $3.6M-95.9% | $88.6M+33.1% | $66.6M+41429.4% | $160K+20.5% | $133K+28.3% | $104K | N/A |
| Current Liabilities | $14.5M-15.0% | $17.1M-35.3% | $26.4M+40.1% | $18.8M+23.3% | $15.3M-49.2% | $30.1M+801.6% | $3.3M-38.9% | $5.5M+51.9% | $3.6M-75.8% | $14.9M+7147.3% | $205K+27.9% | $160K+20.5% | $133K+28.3% | $104K+38.6% | $75K |
| Total Equity | $136.3M+159.7% | $52.5M-50.1% | $105.2M-33.6% | $158.4M+16.1% | $136.4M+1197.2% | -$12.4M-36.7% | -$9.1M-115.5% | $58.7M+236.5% | $17.4M+120.2% | -$86.2M-29.5% | -$66.6M-42827.2% | -$155K-24.8% | -$124K-30.0% | -$96K-40.1% | -$68K |
| Retained Earnings | -$353.3M-6.2% | -$332.7M-23.7% | -$269.0M-32.4% | -$203.2M-42.4% | -$142.7M-337.8% | -$32.6M+77.1% | -$142.2M-19.6% | -$119.0M-9.6% | -$108.6M-25.9% | -$86.2M-36359.1% | -$236K-15.3% | -$205K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
WHWK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$69.3M | -$97.4M-63.6% | -$59.5M+0.2% | -$59.7M-20.2% | -$49.6M-121.4% | -$22.4M-76.5% | -$12.7M+46.8% | -$23.9M-310.7% | -$5.8M+69.2% | -$18.9M-76922.2% | -$25K-12.8% | -$22K-35.7% | -$16K+31.3% | -$23K+4.9% | -$25K-7.7% | -$23K |
| Capital Expenditures | $0 | $552K-66.6% | $1.7M-58.4% | $4.0M+794.6% | $444K+865.2% | $46K+141.8% | $19K-92.0% | $237K+525.0% | $38K+326.2% | $9K-92.1% | $113K | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$69.3M | -$98.0M-60.1% | -$61.2M+3.8% | -$63.6M-27.1% | -$50.1M-122.9% | -$22.5M-76.6% | -$12.7M+47.2% | -$24.1M-312.1% | -$5.8M+69.1% | -$18.9M-13608.6% | -$138K | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$72.2M | $11.9M-52.8% | $25.2M-69.7% | $83.2M+162.6% | -$132.9M-628.3% | $25.2M+132310.2% | -$19K+92.0% | -$237K-525.0% | -$38K-192.2% | $41K | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $81.9M | $94.4M+72496.9% | $130K-60.1% | $326K-99.6% | $72.6M-48.8% | $141.8M+11776.4% | $1.2M | N/A | $48.2M+28.5% | $37.5M+374868.5% | $10K-71.4% | $35K+133.3% | $15K-40.0% | $25K0.0% | $25K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | $0-100.0% | $4.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
WHWK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.4%+1.0pp | 88.4%-0.1pp | 88.5%-2.8pp | 91.2%-8.8pp | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1601.1% | -259.6% | -295.4% | -411.9% | -794.4% | -18.2% | N/A | -55.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -288.3% | -245.1% | -270.0% | -397.7% | -786.4% | -24.8% | N/A | -51.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -15.1%+106.3pp | -121.4%-58.9pp | -62.5%-24.3pp | -38.2%+42.5pp | -80.7% | N/A | N/A | -17.7%+105.0pp | -122.7% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -13.7%+76.9pp | -90.6%-40.9pp | -49.7%-16.8pp | -32.9%+36.9pp | -69.7%-51.2pp | -18.5%+39.8pp | -58.3%-42.1pp | -16.2%+85.6pp | -101.8% | N/A | -169.7% | N/A | -326.8%+10.8pp | -337.6% | N/A |
| Current Ratio | 10.26+6.7x | 3.59-1.1x | 4.72-4.8x | 9.56-0.3x | 9.90+9.3x | 0.62-11.2x | 11.87+0.1x | 11.73+5.9x | 5.82+5.7x | 0.15 | N/A | N/A | N/A | 0.080.0x | 0.09 |
| Debt-to-Equity | 0.11-0.2x | 0.34+0.1x | 0.26+0.1x | 0.160.0x | 0.16 | N/A | N/A | 0.09-0.1x | 0.21 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | -1371.4% | -235.6% | -261.3% | -329.2% | -160.5% | -90.9% | N/A | -29.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Whitehawk Therapeutics Inc Ranks
Frequently Asked Questions
What is Whitehawk Therapeutics Inc's annual revenue?
Whitehawk Therapeutics Inc (WHWK) reported $7.1M in total revenue for fiscal year 2025. This represents a -72.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Whitehawk Therapeutics Inc's revenue growing?
Whitehawk Therapeutics Inc (WHWK) revenue declined by 72.5% year-over-year, from $26.0M to $7.1M in fiscal year 2025.
Is Whitehawk Therapeutics Inc profitable?
No, Whitehawk Therapeutics Inc (WHWK) reported a net income of -$20.6M in fiscal year 2025.
What is Whitehawk Therapeutics Inc's EBITDA?
Whitehawk Therapeutics Inc (WHWK) had EBITDA of -$114.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Whitehawk Therapeutics Inc's gross margin?
Whitehawk Therapeutics Inc (WHWK) had a gross margin of 89.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Whitehawk Therapeutics Inc's return on equity (ROE)?
Whitehawk Therapeutics Inc (WHWK) has a return on equity of -15.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Whitehawk Therapeutics Inc's free cash flow?
Whitehawk Therapeutics Inc (WHWK) recorded an outflow of $98.0M in free cash flow during fiscal year 2025. This represents a -60.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Whitehawk Therapeutics Inc's operating cash flow?
Whitehawk Therapeutics Inc (WHWK) recorded an outflow of $97.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Whitehawk Therapeutics Inc's total assets?
Whitehawk Therapeutics Inc (WHWK) had $150.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Whitehawk Therapeutics Inc's capital expenditures?
Whitehawk Therapeutics Inc (WHWK) invested $552K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Whitehawk Therapeutics Inc spend on research and development?
Whitehawk Therapeutics Inc (WHWK) invested $91.0M in research and development during fiscal year 2025.
What is Whitehawk Therapeutics Inc's current ratio?
Whitehawk Therapeutics Inc (WHWK) had a current ratio of 10.26 as of fiscal year 2025, which is generally considered healthy.
What is Whitehawk Therapeutics Inc's debt-to-equity ratio?
Whitehawk Therapeutics Inc (WHWK) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Whitehawk Therapeutics Inc's return on assets (ROA)?
Whitehawk Therapeutics Inc (WHWK) had a return on assets of -13.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Whitehawk Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Whitehawk Therapeutics Inc (WHWK) had $37.6M in cash against an annual operating cash burn of $97.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Whitehawk Therapeutics Inc's Altman Z-Score?
Whitehawk Therapeutics Inc (WHWK) has an Altman Z-Score of 6.55, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Whitehawk Therapeutics Inc's Piotroski F-Score?
Whitehawk Therapeutics Inc (WHWK) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Whitehawk Therapeutics Inc's earnings high quality?
Whitehawk Therapeutics Inc (WHWK) reported a net loss of $20.6M while operations used $97.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Whitehawk Therapeutics Inc?
Whitehawk Therapeutics Inc (WHWK) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.